文献速递细胞病理与分子病理

原发灶不明癌:靶向治疗时代细胞学与小活检标本的辅助检测

cancer of unknown primary: Ancillary testing of cytologic and small biopsy specimens in the era of targeted therapy.
PubMed 文献 · Cancer Cytopathol · 2018-01-01

本文综述原发灶不明癌(CUP)细胞学与小活检标本的辅助检测策略。在靶向治疗时代,分子检测可能优先于明确组织诊断,因此需审慎管理有限标本。关键形态学模式结合病史和临床影像印象可指导选择有限免疫组化(IPOX)组合以确定宽泛谱系,再用1-2个位点特异性标志物确认诊断,并与临床团队沟通以权衡分子检测优先级。

要点

  • CUP的FNA标本应兼顾诊断与后续研究,需审慎管理有限材料。
  • 基于关键细胞形态学标准和临床影像印象选择有限IPOX组合确定宽泛谱系。
  • 困难病例需与临床团队沟通,分子检测可能优先于追求更明确诊断。

核心结论

  • 在靶向治疗时代,CUP病例中基于细胞形态学和临床沟通审慎选择IPOX检测至关重要。

研究设计与样本

  • 本文为综述,总结作者在遇到CUP时的实践习惯。

主要发现

  • 关键形态学模式结合患者病史和临床影像印象可指导选择有限IPOX组合以确定宽泛谱系。
  • 随后可用1-2个位点特异性标志物确认诊断。
  • 困难病例中,向治疗医生传达情况可能有助,其可能优先选择分子检测而非追求更明确诊断。

临床怎么用

  • CUP的FNA应同时用于诊断和获取组织进行额外研究。
  • 根据关键细胞形态学标准和与临床团队持续沟通,审慎选择IPOX检测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Initial evaluation of patients presenting with a suspected malignancy without a clear clinical or radiologic impression of a primary site (so-called cancer of unknown primary, or CUP) frequently includes fine needle aspiration (FNA) to both establish a diagnosis and procure tissue for additional studies. Careful management of limited specimen material is especially important in the modern era, when molecular studies may take precedence over a more definitive tissue diagnosis. This review summarizes our practice habits when encountering a CUP. Broadly, key morphologic patterns in context of patient history and clinical-radiologic impression should guide the selection of a limited panel of IPOX stains to establish first a broad lineage. Subsequently 1-2 site-specific markers may be used to confirm the diagnosis. In difficult cases, it is helpful to convey the situation to the treating physicians, who may prefer to prioritize molecular testing over pursuit of a more definitive diagnosis. Prudent choice of immunoperoxidase (IPOX) studies, based on both key cytomorphologic criteria and continued communications with the clinical team regarding their needs for treatment planning, is critical in CUP cases.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Cowan ML, VandenBussche CJ. cancer of unknown primary: Ancillary testing of cytologic and small biopsy specimens in the era of targeted therapy. Cancer Cytopathol. 2018. PMID: 30156769. doi:10.1002/cncy.22014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。